These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 19787038)
21. An Update on African Trypanocide Pharmaceutics and Resistance. Kasozi KI; MacLeod ET; Ntulume I; Welburn SC Front Vet Sci; 2022; 9():828111. PubMed ID: 35356785 [TBL] [Abstract][Full Text] [Related]
22. Drug transport and drug resistance in African trypanosomes. Mäser P; Lüscher A; Kaminsky R Drug Resist Updat; 2003 Oct; 6(5):281-90. PubMed ID: 14643298 [TBL] [Abstract][Full Text] [Related]
24. Rapid identification of isometamidium-resistant stocks of Trypanosoma b. brucei by PCR-RFLP. Afework Y; Mäser P; Etschmann B; von Samson-Himmelstjerna G; Zessin KH; Clausen PH Parasitol Res; 2006 Aug; 99(3):253-61. PubMed ID: 16541260 [TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of alternative treatments of African gambiense trypanosomiasis in Uganda. Politi C; Carrín G; Evans D; Kuzoe FA; Cattand PD Health Econ; 1995; 4(4):273-87. PubMed ID: 8528430 [TBL] [Abstract][Full Text] [Related]
26. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Legros D; Evans S; Maiso F; Enyaru JC; Mbulamberi D Trans R Soc Trop Med Hyg; 1999; 93(4):439-42. PubMed ID: 10674099 [TBL] [Abstract][Full Text] [Related]
27. The trypanocide diminazene aceturate is accumulated predominantly through the TbAT1 purine transporter: additional insights on diamidine resistance in african trypanosomes. de Koning HP; Anderson LF; Stewart M; Burchmore RJ; Wallace LJ; Barrett MP Antimicrob Agents Chemother; 2004 May; 48(5):1515-9. PubMed ID: 15105099 [TBL] [Abstract][Full Text] [Related]
28. [A trial treatment with eflornithine of trypanosomiasis caused by Trypanosoma brucei gambiense in the Peoples Republic of the Congo]. Eozenou P; Jannin J; Ngampo S; Carme B; Tell GP; Schechter PJ Med Trop (Mars); 1989; 49(2):149-54. PubMed ID: 2507863 [TBL] [Abstract][Full Text] [Related]
29. [Treatment of sleeping disease caused by trypanosoma brucei gambiense with alpha-difluoromethylornithine (DFMO) in a rural hospital in Zaire]. De Groof D; Bruneel H; Musumari TS; Ruppol JF Med Trop (Mars); 1992; 52(4):369-75. PubMed ID: 1494306 [TBL] [Abstract][Full Text] [Related]
30. Population genetics of Trypanosoma brucei gambiense in sleeping sickness patients with treatment failures in the focus of Mbuji-Mayi, Democratic Republic of the Congo. Pyana PP; Sere M; Kaboré J; De Meeûs T; MacLeod A; Bucheton B; Van Reet N; Büscher P; Belem AMG; Jamonneau V Infect Genet Evol; 2015 Mar; 30():128-133. PubMed ID: 25535944 [TBL] [Abstract][Full Text] [Related]
31. Apparent lack of a domestic animal reservoir in Gambiense sleeping sickness in northwest Uganda. Balyeidhusa AS; Kironde FA; Enyaru JC Vet Parasitol; 2012 Jun; 187(1-2):157-67. PubMed ID: 22245071 [TBL] [Abstract][Full Text] [Related]
32. Chemotherapy for second-stage Human African trypanosomiasis. Lutje V; Seixas J; Kennedy A Cochrane Database Syst Rev; 2010 Aug; (8):CD006201. PubMed ID: 20687080 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Burri C; Nkunku S; Merolle A; Smith T; Blum J; Brun R Lancet; 2000 Apr; 355(9213):1419-25. PubMed ID: 10791526 [TBL] [Abstract][Full Text] [Related]
34. Advances in sleeping sickness therapy. Van Nieuwenhove S Ann Soc Belg Med Trop; 1992; 72 Suppl 1():39-51. PubMed ID: 1417168 [TBL] [Abstract][Full Text] [Related]
35. Susceptibility of Grammomys surdaster thicket rats to Trypanosoma brucei gambiense infection. Büscher P; Bin Shamamba SK; Ngoyi DM; Pyana P; Baelmans R; Magnus E; Van Overmeir C Trop Med Int Health; 2005 Sep; 10(9):850-5. PubMed ID: 16135191 [TBL] [Abstract][Full Text] [Related]
36. Treatment of human late stage gambiense trypanosomiasis with alpha-difluoromethylornithine (eflornithine): efficacy and tolerance in 14 cases in Côte d'Ivoire. Doua F; Boa FY; Schechter PJ; Miézan TW; Diai D; Sanon SR; De Raadt P; Haegele KD; Sjoerdsma A; Konian K Am J Trop Med Hyg; 1987 Nov; 37(3):525-33. PubMed ID: 3120607 [TBL] [Abstract][Full Text] [Related]
37. Front-line glioblastoma chemotherapeutic temozolomide is toxic to Trypanosoma brucei and potently enhances melarsoprol and eflornithine. Steverding D; Rushworth SA Exp Parasitol; 2017 Jul; 178():45-50. PubMed ID: 28552794 [TBL] [Abstract][Full Text] [Related]
38. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. Bisser S; N'Siesi FX; Lejon V; Preux PM; Van Nieuwenhove S; Miaka Mia Bilenge C; Būscher P J Infect Dis; 2007 Feb; 195(3):322-9. PubMed ID: 17205469 [TBL] [Abstract][Full Text] [Related]
39. Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo. Balasegaram M; Harris S; Checchi F; Ghorashian S; Hamel C; Karunakara U Bull World Health Organ; 2006 Oct; 84(10):783-91. PubMed ID: 17128358 [TBL] [Abstract][Full Text] [Related]
40. Drug resistance in human African trypanosomiasis. Barrett MP; Vincent IM; Burchmore RJ; Kazibwe AJ; Matovu E Future Microbiol; 2011 Sep; 6(9):1037-47. PubMed ID: 21958143 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]